Industry executives and thought leaders BRG spoke to universally expect to see a rebound in sector deal activity following a couple of years of sluggish activity where global healthcare mergers and acquisitions (M&A) volume declined nearly 30% (less than half of the more than $500 billion in 2021). Inflation, higher interest rates and heightened regulatory pressures put a strain on dealmakers who have been driven by the need to gain efficiencies, accelerate growth, and integrate new technologies and services. Fortunately, several factors are expected to bolster transactions in 2025.
Read the full article: BRG: 2025 US Healthcare & Life Sciences Transactions Outlook //
Source: https://media.thinkbrg.com/wp-content/uploads/2025/03/31124843/2025-US-Healthcare-and-Life-Sciences-Transactions-Outlook.pdf